Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
The Path of a Healthtech CTO with Margaret McKenna
The AI-Flipped Clinic with Zak Kohane
Putting the Pro in Provider Networks with Dan Rosenthal
The Exec Hiring Playbook with Ben Horowitz and Ali Ghodsi
Drugging the Undruggable with Greg Verdine
Forecasting Human Health with Jeffrey Kaditz
Will AI Kill Us All? with Marc Andreessen
AI, Innovation, and Regulatory Insights with Amy Abernethy
From Faculty to Founder: Building Startups from Academia
Curing the Trust Problem with Mark Cuban
The Founders Reinventing Healthcare with Fintech
Adapting Biopharma to AI with Greg Meyers
Healthcare x Fintech with Julie Yoo and David Haber
Journal Club: Engineering Logic into CAR T Therapies with Robbie Majzner
The Future of Cheese with Magi Richani
Reengineering Healthcare and Medicine with Technology with Vineeta Agarwala
Bio x American Dynamism with Katherine Boyle and David Ulevitch
Shaping Channel Partnerships with Sean Duffy
Strategizing Channel Partnerships with Florian Otto
AI and Actionable Insights for Drug Development with Daphne Koller
Create your
podcast in
minutes
It is Free